Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 04 Oct 2016
Crizotinib in NSCLC: new data are inconclusive
4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue. ...
Posted by Michael Wonder on 04 Oct 2016
Ibrutinib in CLL: no additional clinical benefits for treatment-naïve patients
4 October 2016 - The dossier contains no suitable data on first-line use. ...
Posted by Michael Wonder on 26 Sep 2016
Nivolumab plus ipilimumab in melanoma: added benefit in certain patients
15 September 2016 - Survival advantage in BRAF V600 wild type tumour depends on gender / severe side effects more common. ...
Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
Posted by Michael Wonder on 17 Sep 2016
Selexipag in pulmonary arterial hypertension: additional clinical benefit is not proven
16 September 2016 - Limited comparator therapy and division of population inadequate/the only study compared the medicine with placebo. ...
Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects. ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...
Posted by Michael Wonder on 07 Sep 2016
IQWiG Autumn Symposium 2016: programme is now online
6 September 2016 - More light than shadow? Beneficial and hindering factors for successful clinical studies. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 15 Aug 2016
Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered
15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients. ...
Posted by Michael Wonder on 06 Aug 2016
Brivaracetam in epilepsy: additional clinical benefits not seen as before
4 August 2016 - The new indirect comparison is methodologically better but there is still no evidence of an additional ...
Posted by Michael Wonder on 03 Aug 2016
Germany plans to extend price brake for drugs under statutory insurance
25 July 2016 - Germany wants to extend a price brake for drugs covered by statutory health insurance for five years ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...